Action VYGR VOYAGER THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Voyager Therapeutics, Inc.

Actions

VYGR

US92915B1061

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 28/06/2024 		Varia. 5j. Varia. 1 janv.
7,91 USD +0,64% Graphique intraday de Voyager Therapeutics, Inc. -2,22% -6,28%
13/06 Voyager Therapeutics, Inc. nomme Nathan Jorgensen au poste de directeur financier et de directeur comptable, à compter du 8 juillet 2024 au plus tard. CI
16/05 Voyager Therapeutics, Inc. annonce le dosage des premiers participants à l'essai à dose unique ascendante de VY-TAU01 pour le traitement de la maladie d'Alzheimer CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
Voyager Therapeutics Names Nathan Jorgensen as Finance Chief
Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Principal Financial Officer, and Principal Accounting Officer, Effective No Later Than July 8, 2024
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer?s Disease
Voyager Therapeutics: Q1 Earnings Snapshot
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
Voyager Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Voyager Therapeutics Presents Data for Second-Generation, TRACER-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER??-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer
Voyager Therapeutics, Inc. Announces CFO Changes
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action VYGR
  4. Actualités Voyager Therapeutics, Inc.
  5. Autres langues